Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	20.61B
Revenue (ttm)	1.68B
Net Income (ttm)	598.95M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	34.41
Forward PE	32.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	677
Open	2.700
Previous Close	2.700
Day's Range	2.700 - 2.700
52-Week Range	1.880 - 5.580
Beta	0.63
RSI	22.92
Earnings Date	May 27, 2025

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2024, HNSPF's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY